Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Shares Shorted: Short Interest Up 56.8% in September

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 2,067,445 shares, a growth of 56.8% from the September 15th total of 1,318,893 shares. Based on an average daily volume of 569,389 shares, the days-to-cover ratio is currently 3.6 days. Currently, 8.6% of the company’s shares are short sold.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock opened at $18.80 on Friday. The company has a market capitalization of $485.79 million, a P/E ratio of -0.13 and a beta of -0.29. The company’s 50 day simple moving average is $31.39. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, equities analysts predict that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on FTH shares. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Guggenheim began coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 16th. They set a “buy” rating and a $70.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Finally, Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $56.25.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at about $307,000. Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares in the last quarter. Bank of America Corp DE raised its stake in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares in the last quarter. Stempoint Capital LP bought a new position in Sensei Biotherapeutics in the first quarter worth about $4,188,000. Finally, Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics in the second quarter worth about $3,610,000. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.